CMR Versius Robotic Platform in Urinary Tract Tumors: A Tertiary Center Experience

Objectives To evaluate the safety and efficacy of the Versius® robotic surgical platform (CMR Surgical, Cambridge, UK) in the surgical management of urological malignancies. Methods This prospective observational study included 45 patients with urological malignancies who were eligible for minimally invasive surgery between May 2023 and May 2024. Patients underwent robotic procedures using the Versius® platform. Perioperative, postoperative, and pathological outcomes were prospectively collected and analyzed. Results Among the 45 patients, the most frequently performed procedure was robot-assisted radical prostatectomy (RARP) (n = 26, 57.8%). Robot-assisted radical cystectomy (RARC) was performed in 5 patients (11%), robot-assisted radical nephrectomy (RARN) in 3 (6%), robot-assisted partial nephrectomy (RAPN) in 8 (18%), robot-assisted nephroureterectomy (RANU) in 2 (4%), and robot-assisted adrenalectomy (RAA) in 1 patient (2%). Mean operative times were 307.8, 318, 325.2, 258.6, 285, and 135 minutes for RARP, RARC, RARN, RAPN, RANU, and RAA, respectively. Median length of hospital stay was 3 days for RARP, 7 days for RARC, 2 days for RARN, 3 days for RAPN, 17 days for RANU, and 4 days for RAA. Conversion to conventional laparoscopy occurred in 4 patients (8.9%), while conversion to open surgery was required in 2 patients (4.4%). Postoperative complications were reported in 13 patients (28.9%), with the majority being low-grade according to the Clavien–Dindo classification. Conclusions The Versius® (CMR Surgical, Cambridge, UK) robotic surgical platform appears to be a safe and effective option for the management of a wide range of urological malignancies, with acceptable perioperative outcomes and a manageable learning curve. Larger prospective studies with long-term oncological and functional follow-up are required to further validate these findings.